Real-world outcomes in patients with AML and MDS treated with Azacitidine

被引：0
|
作者：
Prusak, E. [1 ]
Lawes, M. [2 ]
Collins, A. [2 ]
机构：
[1] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England
[2] Norfolk & Norwich Univ Hosp, Haematol, Norwich, Norfolk, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
AML; Azacitidine; mds;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-PO-0
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [21] Predictors of Outcomes in Patients With MECOM EVI1 Rearranged AML or MDS
    Kusne, Yael
    McGary, Alyssa
    Kelemen, Katalin
    Litzow, Mark
    Al-Kali, Aref
    Foran, James
    Badar, Talha
    Patnaik, Mrinal
    Mangaonkar, Abhishek
    Sproat, Lisa
    Palmer, Jeanne
    Greipp, Patricia
    Yi, Cecilia Arana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S318 - S318
  • [22] Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs
    Collomb, Erwann
    Bourguignon, Laurent
    Tichadou, Antoine
    Roche, Pauline
    Berton, Guillaume
    Ciccolini, Joseph
    Colle, Julien
    Farnault, Laure
    Costello, Regis
    Fanciullino, Raphaelle
    Venton, Geoffroy
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (02)
  • [23] Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population
    Jain, Hasmukh
    Eipe, Thomas
    Shetty, Alok
    Nayak, Lingaraj
    Bagal, Bhausaheb Pandurang
    Sharma, Neha
    Pawar, Akash
    Sengar, Manju
    JCO GLOBAL ONCOLOGY, 2025, 11
  • [24] Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
    Schroeder, T.
    Czibere, A.
    Platzbecker, U.
    Bug, G.
    Uharek, L.
    Luft, T.
    Giagounidis, A.
    Zohren, F.
    Bruns, I.
    Wolschke, C.
    Rieger, K.
    Fenk, R.
    Germing, U.
    Haas, R.
    Kroeger, N.
    Kobbe, G.
    LEUKEMIA, 2013, 27 (06) : 1229 - 1235
  • [25] Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia
    Voso, Maria Teresa
    Niscola, Pasquale
    Piciocchi, Alfonso
    Fianchi, Luana
    Maurillo, Luca
    Musto, Pellegrino
    Pagano, Livio
    Mansueto, Giovanna
    Criscuolo, Marianna
    Aloe-Spiriti, Maria Antonietta
    Buccisano, Francesco
    Venditti, Adriano
    Tendas, Andrea
    Piccioni, Anna Lina
    Zini, Gina
    Latagliata, Roberto
    Filardi, Nunzio
    Fragasso, Alberto
    Fenu, Susanna
    Breccia, Massimo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (04) : 344 - 351
  • [26] Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
    Rajakumaraswamy, Nishanthan
    Gandhi, Mitul
    Wei, Andrew H.
    Sallman, David A.
    Daver, Naval G.
    Mo, Shuyuan
    Iqbal, Shahed
    Karalliyadda, Roshan
    Chen, Manli
    Wang, Yunfei
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04) : 260 - 268.e2
  • [27] Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
    T Schroeder
    A Czibere
    U Platzbecker
    G Bug
    L Uharek
    T Luft
    A Giagounidis
    F Zohren
    I Bruns
    C Wolschke
    K Rieger
    R Fenk
    U Germing
    R Haas
    N Kröger
    G Kobbe
    Leukemia, 2013, 27 : 1229 - 1235
  • [28] Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
    U Platzbecker
    M Wermke
    J Radke
    U Oelschlaegel
    F Seltmann
    A Kiani
    I-M Klut
    H Knoth
    C Röllig
    J Schetelig
    B Mohr
    X Graehlert
    G Ehninger
    M Bornhäuser
    C Thiede
    Leukemia, 2012, 26 : 381 - 389
  • [29] Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy
    Yoshida, Chikashi
    Kondo, Takeshi
    Ito, Tomoki
    Kizaki, Masahiro
    Yamamoto, Kazuhiko
    Miyamoto, Toshihiro
    Morita, Yasuyoshi
    Eto, Tetsuya
    Katsuoka, Yuna
    Takezako, Naoki
    Uoshima, Nobuhiko
    Imada, Kazunori
    Ando, Jun
    Komeno, Takuya
    Mori, Akio
    Ishikawa, Yuichi
    Satake, Atsushi
    Watanabe, Junichi
    Kawakami, Yoshiko
    Morita, Tetsuo
    Taneike, Ikue
    Nakayama, Masahiko
    Duan, Yinghui
    Garbayo Guijarro, Belen
    Delgado, Alexander
    Llamas, Cynthia
    Kiyoi, Hitoshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) : 89 - 101
  • [30] Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine
    Massimo Breccia
    Adriano Salaroli
    Giuseppina Loglisci
    Giuliana Alimena
    Annals of Hematology, 2013, 92 : 411 - 412
12345